Sophiris Bio, Inc. (SPHS) to Release Earnings on Tuesday
Sophiris Bio, Inc. (NASDAQ:SPHS) is scheduled to release its earnings data on Tuesday, November 7th. Analysts expect Sophiris Bio to post earnings of ($0.10) per share for the quarter.
Shares of Sophiris Bio, Inc. (SPHS) opened at $2.17 on Friday. Sophiris Bio, Inc. has a one year low of $1.80 and a one year high of $3.24.
An institutional investor recently raised its position in Sophiris Bio stock. Vanguard Group Inc. increased its stake in shares of Sophiris Bio, Inc. (NASDAQ:SPHS) by 1.0% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 731,437 shares of the biopharmaceutical company’s stock after purchasing an additional 7,600 shares during the period. Vanguard Group Inc. owned approximately 2.43% of Sophiris Bio worth $1,609,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 5.78% of the company’s stock.
A number of equities analysts recently weighed in on the stock. Maxim Group set a $6.00 price objective on shares of Sophiris Bio and gave the stock a “buy” rating in a research report on Monday, October 2nd. HC Wainwright set a $6.00 price objective on shares of Sophiris Bio and gave the stock a “buy” rating in a research report on Friday, August 11th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $6.60.
Sophiris Bio Company Profile
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.